Things Are About To Get Hairy!
As the name suggests, No-Shave November is an annual event during which participants forgo shaving and other hair trimming in…
10/25/2022
Things Are About To Get Hairy!
As the name suggests, No-Shave November is an annual event during which participants forgo shaving and other hair trimming in…
10/12/2022
Create a Legacy with AIM
October 17th – 23rd, 2022 is National Estate Planning Awareness Week Creating a legacy gift that supports melanoma research in…
|
10/11/2022
Talking to Your Care Team about Your Sexual Orientation and Gender Identity
While it may be an uncomfortable topic to bring up, sharing your sexual orientation and gender identity with your cancer…
|
09/30/2022
Giving immunotherapy before targeted therapy improves survival in patients with advanced melanoma
(Source:Georgetown University Medical Center) Originally published Sep 27, 2022, Medical Life Sciences Giving immunotherapy before targeted therapy improves survival in…
|
09/29/2022
Val Guild Honored at 2022 ASCO Annual Conference
by Alicia Rowell, Vice President Saturday, June 4 was a special evening. In Chicago that week many of the nation’s…
|
09/27/2022
President’s Letter | September 2022
From the Desk of Samantha Guild Leaves are falling, pumpkins are out, football is on TV, and the kids are…
|
09/27/2022
AIM Welcomes Ann Garst Taylor as New Director of Community Engagement
By Mara Klecker Ann Garst Taylor, AIM at Melanoma’s new Director of Community Engagement, has nearly 30 years of volunteer…
|
09/16/2022
Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag , for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%
(NEWS PROVIDED BY Bristol Myers Squibb, September 16, 2022, ) Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the…
|
09/13/2022
Spirituality and Cancer Care With Michael Eselun, BCC
When faced with a cancer diagnosis, some patients rely on their spirituality to cope and find meaning behind the experience.…
|
09/13/2022
ESMO: TIL therapy improves on Yervoy in melanoma trial
(NEWS PROVIDED BY Pharmaphorum, September 11, 2022, Phil Taylor) A personalised cell therapy based on tumour-infiltrating lymphocyte (TIL) cells has…
|
Recent Posts
Jan. 21, 2025
Replimune Announces BLA Acceptance and Priority Review for RP1 for the Treatment in Advanced Melanoma
Jan. 14, 2025
Meaning-Centered Psychotherapy: Finding Purpose in the Face of Cancer
Jan. 09, 2025
What Inspires Leading Melanoma Researchers?
Dec. 30, 2024
Jimmy Carter: A Life that Shaped Cancer Treatment and Hope for Melanoma Patients
Dec. 27, 2024